AU2003237351B2 - Novel recombinant anticoagulant proteins - Google Patents

Novel recombinant anticoagulant proteins Download PDF

Info

Publication number
AU2003237351B2
AU2003237351B2 AU2003237351A AU2003237351A AU2003237351B2 AU 2003237351 B2 AU2003237351 B2 AU 2003237351B2 AU 2003237351 A AU2003237351 A AU 2003237351A AU 2003237351 A AU2003237351 A AU 2003237351A AU 2003237351 B2 AU2003237351 B2 AU 2003237351B2
Authority
AU
Australia
Prior art keywords
anv
seq
recombinant
kpi
tap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003237351A
Other languages
English (en)
Other versions
AU2003237351A1 (en
AU2003237351A2 (en
Inventor
Tze Chein Wun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2003237351A1 publication Critical patent/AU2003237351A1/en
Publication of AU2003237351A2 publication Critical patent/AU2003237351A2/en
Application granted granted Critical
Publication of AU2003237351B2 publication Critical patent/AU2003237351B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003237351A 2002-06-06 2003-06-04 Novel recombinant anticoagulant proteins Ceased AU2003237351B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38693202P 2002-06-06 2002-06-06
US60/386,932 2002-06-06
PCT/US2003/017442 WO2003103577A2 (en) 2002-06-06 2003-06-04 Novel recombinant anticoagulant proteins

Publications (3)

Publication Number Publication Date
AU2003237351A1 AU2003237351A1 (en) 2003-12-22
AU2003237351A2 AU2003237351A2 (en) 2003-12-22
AU2003237351B2 true AU2003237351B2 (en) 2009-12-03

Family

ID=29736237

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003237351A Ceased AU2003237351B2 (en) 2002-06-06 2003-06-04 Novel recombinant anticoagulant proteins

Country Status (8)

Country Link
US (2) US7378393B2 (enExample)
EP (1) EP1509541B1 (enExample)
JP (1) JP4444821B2 (enExample)
CN (1) CN1659180B (enExample)
AT (1) ATE534658T1 (enExample)
AU (1) AU2003237351B2 (enExample)
CA (1) CA2486362A1 (enExample)
WO (1) WO2003103577A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7671013B2 (en) * 2003-04-03 2010-03-02 Canadian Blood Services, Inc. Coagulation proteins, coagulation-anticoagulation protein complexes, derivatives thereof and their uses
CA2559167A1 (en) * 2004-03-11 2005-09-22 Alavita, Inc. Modified annexin proteins and methods for preventing thrombosis
US7511016B2 (en) 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
HRP20120797T1 (hr) 2007-12-18 2012-12-31 Athera Biotechnologies Ab Spojevi i postupci za lijeäśenje vaskularne bolesti
JP2011512393A (ja) * 2008-02-22 2011-04-21 アセラ・バイオテクノロジーズ・アーベー 再狭窄の予防または治療のための化合物および方法
WO2010043045A1 (en) 2008-10-17 2010-04-22 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
US8691771B2 (en) 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
CN113956339B (zh) * 2021-10-28 2023-02-24 中国药科大学 宽体金线蛭抗凝血因子XIa多肽及其应用
CN116444640A (zh) * 2022-09-26 2023-07-18 昆明医科大学 一种版纳绳蚋抗栓肽Sibanin及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0965597A1 (en) * 1996-12-27 1999-12-22 Mochida Pharmaceutical Co., Ltd. Cell membrane-directed drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007676A1 (fr) 1987-03-27 1988-10-06 Terumo Kabushiki Kaisha Capteur enzymatique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0965597A1 (en) * 1996-12-27 1999-12-22 Mochida Pharmaceutical Co., Ltd. Cell membrane-directed drugs

Also Published As

Publication number Publication date
WO2003103577A2 (en) 2003-12-18
CN1659180B (zh) 2010-06-02
EP1509541A2 (en) 2005-03-02
US20050164926A1 (en) 2005-07-28
US20090029444A1 (en) 2009-01-29
JP2005528124A (ja) 2005-09-22
EP1509541A4 (en) 2006-06-07
EP1509541B1 (en) 2011-11-23
ATE534658T1 (de) 2011-12-15
AU2003237351A1 (en) 2003-12-22
AU2003237351A2 (en) 2003-12-22
WO2003103577A3 (en) 2004-03-04
US7378393B2 (en) 2008-05-27
JP4444821B2 (ja) 2010-03-31
CN1659180A (zh) 2005-08-24
CA2486362A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
US20090029444A1 (en) Novel recombinant anticoagulant proteins
US5874407A (en) Factor VIIA inhibitors
CA2678001C (en) Therapeutic application of kazal-type serine protease inhibitors
US5786328A (en) Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) Kunitz type plasma kallikrein inhibitors
US6113896A (en) Pharmaceutical compositions containing ecotin and homologs thereof
JP3345420B2 (ja) 新規のヒトクニツ型プロテアーゼインヒビター及びその変異体
EP0486001A1 (en) Recombinant urinary trypsin inhibitor fragments and drug composition
CZ284911B6 (cs) Lidská varianta inhibitoru proteasy Kunitzova typu
JPH03255099A (ja) プロテイナーゼ阻害因子、それらの調製方法およびそれらを含有する薬物
JP2012525836A (ja) セリンプロテアーゼインヒビターの改変方法
KR20110114587A (ko) 세린 프로테아제 유도체 및 혈액응고 장애의 치료 또는 예방의 용도
EP0866870B1 (en) TISSUE FACTOR - KUNITZ DOMAIN FUSION PROTEINS AS FACTOR VIIa INHIBITORS
US20250011379A1 (en) Complement factor i-related compositions and methods
JP2010533684A (ja) 血液凝固異常の治療又は予防のための変異アンチトロンビンの使用
US5583111A (en) Thrombin inhibitors
Chen et al. Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants
EP2600891B1 (en) Protein fusion constructs possessing thrombolytic and anticoagulant properties
WO2015002611A9 (en) Compositions and methods for inhibiting thrombogenesis
JP2009528831A (ja) キメラＫｕｎｉｔｚドメインおよびその使用
JPH04210700A (ja) 組換ヒトトロンボモジュリン誘導体
JP4339962B2 (ja) ヒトアンチトロンビン変異体
US6841534B2 (en) Protein Z-dependent protease inhibitor
JP2000503528A (ja) 第ＶＩＩａ因子の新規阻害剤
AU2008214916B2 (en) Therapeutic application of Kazal-type serine protease inhibitors

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 DEC 2004

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired